Postma MJ - Search Results

1

Cost-effectiveness of vaccination against herpes zoster.

de Boer PT, Wilschut JC, Postma MJ. de Boer PT, et al. Among authors: postma mj. Hum Vaccin Immunother. 2014;10(7):2048-61. doi: 10.4161/hv.28670. Hum Vaccin Immunother. 2014. PMID: 25424815 Free PMC article. Review.

2

Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence.

Postma MJ, Baltussen RM, Heijnen ML, de Berg LT, Jager JC. Postma MJ, et al. Drugs Aging. 2000 Sep;17(3):217-27. doi: 10.2165/00002512-200017030-00005. Drugs Aging. 2000. PMID: 11043820 Review.

3

Cost effectiveness of expanded antenatal HIV testing in London.

Postma MJ, Beck EJ, Hankins CA, Mandalia S, Jager JC, de Jong-van den Berg LT, Walters MD, Sherr L. Postma MJ, et al. AIDS. 2000 Oct 20;14(15):2383-9. doi: 10.1097/00002030-200010200-00020. AIDS. 2000. PMID: 11089627

4

Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands.

Postma MJ, Heijnen ML, Jager JC. Postma MJ, et al. Pharmacoeconomics. 2001;19(2):215-22. doi: 10.2165/00019053-200119020-00008. Pharmacoeconomics. 2001. PMID: 11284385

5

Cost-effectiveness of periconceptional supplementation of folic acid.

Postma MJ, Londeman J, Veenstra M, de Walle HE, de Jong-van den Berg LT. Postma MJ, et al. Pharm World Sci. 2002 Feb;24(1):8-11. doi: 10.1023/a:1014848928212. Pharm World Sci. 2002. PMID: 11980171

6

[Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis].

Postma MJ, Heijnen ML, Beutels P, Jager JC. Postma MJ, et al. Ned Tijdschr Geneeskd. 2002 May 4;146(18):855-9. Ned Tijdschr Geneeskd. 2002. PMID: 12038224 Dutch.

7

Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands.

Bos JM, Rümke H, Welte R, Postma MJ. Bos JM, et al. Among authors: postma mj. Clin Ther. 2003 Oct;25(10):2614-30. doi: 10.1016/s0149-2918(03)80322-3. Clin Ther. 2003. PMID: 14667962

8

Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands.

Postma MJ, van Hulst M, De Wolf JT, Botteman M, Staginnus U. Postma MJ, et al. Transfus Med. 2005 Oct;15(5):379-87. doi: 10.1111/j.1365-3148.2005.00609.x. Transfus Med. 2005. PMID: 16202052

9

Systematic screening for Chlamydia trachomatis: estimating cost-effectiveness using dynamic modeling and Dutch data.

de Vries R, van Bergen JE, de Jong-van den Berg LT, Postma MJ; PILOT-CT Study Group. de Vries R, et al. Among authors: postma mj. Value Health. 2006 Jan-Feb;9(1):1-11. doi: 10.1111/j.1524-4733.2006.00075.x. Value Health. 2006. PMID: 16441519 Free article.

10

Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).

Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, Gansevoort RT, de Jong PE, de Jong-van den Berg LT, Postma MJ; PREVEND IT Study Group. Atthobari J, et al. Among authors: postma mj. Clin Ther. 2006 Mar;28(3):432-44. doi: 10.1016/j.clinthera.2006.03.012. Clin Ther. 2006. PMID: 16750458

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

654 results

Search Page